Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3

Longer follow-up data for 1-year transfusion independence in IMerge Phase 3, which demonstrated statistically significant and clinically meaningful continuous, durable efficacy



Strong... | May 11, 2023

Related Keywords

Germany ,Paris ,France General ,France ,Leipzig ,Sachsen ,United States ,America ,Faye Feller ,Nicolas Chatain ,Mikkael Sekeres ,Nicolas Chapuis ,Valeria Santini ,Uwe Platzbecker ,University Hospital Of Leipzig ,Drug Administration ,Sylvester Comprehensive Cancer Center ,Linkedin ,University Hospital Aachen ,European Hematology Association ,Geron Corporation Nasdaq ,International Working Group ,University Of Miami Health System ,University Of Florence School Medicine ,Geron Corporation ,Annual Meeting ,Executive Vice President ,Chief Medical Officer ,Lower Risk Myelodysplastic Syndromes ,Transfusion Independence ,Heavily Transfused Non Del ,Erythropoiesis Stimulating Agents ,University Hospital ,Modifying Activity ,Florence School ,Patient Reported Fatigue ,Miami Health System ,Sylvester Comprehensive Cancer ,Functional Assessment ,Chronic Illness Therapy ,Working Group ,Lower Risk ,Assistance Publique Hopitaux De Paris ,Centre Universite Paris ,Pre Clinical Data ,Myeloproliferative Neoplasm ,North America ,Middle East ,Fast Track ,New Drug Application ,Marketing Authorization Application ,Nobel Prize Winning ,Geron Corporation Stock Exchange ,News ,Information ,Press Release ,Longer ,Data ,Or ,Transfusion ,Independence ,N ,Merge ,Hase ,Which ,Remonstrated ,Statistically ,Significant ,End ,Linically ,Meaningful ,Urable Gern Us3741631036 ,